Propentofylline
From Wikipedia, the free encyclopedia
 |
|
|
Propentofylline
|
|
| Systematic (IUPAC) name | |
| 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C15H22N4O3 |
| Mol. mass | 306.360 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Propentofylline is a xanthine derivative and phosphodiesterase inhibitor with purported neuroprotective effects. It is being studied as a possible treatment for Alzheimer's disease and multi-infarct dementia.[1][2]
Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[3][4]
[edit] See also
[edit] References
- ^ Frampton M, Harvey RJ, Kirchner V (2003). "Propentofylline for dementia". Cochrane database of systematic reviews (Online) (2): CD002853. doi:. PMID 12804440.
- ^ Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–16. PMID 9329701.
- ^ Bath PM, Bath-Hextall FJ (2004). "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000162. doi:. PMID 15266424.
- ^ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. PMID 8478410.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||
